REFERENCES
1. Ross CJD, Visscher H, Rod Rassekh S, Castro-Pastrana LI, Shereck E, et al. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol 2011;18:134-51.
2. Conyers R, Devaraja S, Elliott D. Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatr Blood Cancer 2018;65:e26937.
3. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92:414-7.
4. Rodríguez AE, Herrero MJ, Bernal ML, Rojas L, Peiró AM. Personalized medicine into health national services: barriers and potentialities. Drug Metab Pers Ther 2018; doi: 10.1515/dmpt-2018-0017.
5. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med 2017;19:215-23.
6. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-Van Der Zee AH, et al. Pharmacogenetics: from Bench to Byte - an update of guidelines. Clin Pharmacol Ther 2011;89:662-73.
7. García-González X, Cabaleiro T, Herrero MJ, McLeod H, López-Fernández LA. Clinical implementation of pharmacogenetics. Drug Metab Pers Ther 2016;31:9-16.
8. U S Food and Drug Administration. Available from: https://www.fda.gov/. [Last accessed on 18 Feb 2019].
9. European Medicines Agency. Available from: https://www.ema.europa.eu/en. [Last accessed on 18 Feb 2019].
10. Pharmaceuticals and Medical Devices Agency. Available from: http://www.pmda.go.jp/english/. [Last accessed on 18 Feb 2019].
11. Drugs and Health Products - Canada.ca. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products.html. [Last accessed on 18 Feb 2019].
12. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011;89:464-7.
13. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, et al. Pharmacogenetics: from Bench to Byte. Clin Pharmacol Ther 2008;83:781-7.
14. Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, et al. A comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Groups. Clin Pharmacol Ther 2018;103:599-618.
15. Lee JW, Pussegoda K, Rassekh SR, Liu G, Hwang S, et al. Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using Pharmacogenetic markers. Ther Drug Monit 2016;38:423-31.
16. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven Leeder J. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 2017;19:69-76.
17. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-91.
18. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. Clinical pharmacogentics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 Update. Clin Pharmacol Ther 2013;93:324-5.
19. Relling MV, Schaw M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 2018; doi: 10.1002/cpt.1304.
20. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 2018;103:210-6.
21. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 2017;102:213-8.
22. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and Tamoxifen therapy. Clin Phramacol Ther 2018;103:770-7.
23. Alsous M, Yousef AM, Abdel Jalil M, Zawiah M, Yacoub S, et al. Genetic Polymorphism of Thiopurine S-methyltransferase in Children with Acute Lymphoblastic Leukemia in Jordan. Asian Pac J Cancer Prev 2018;19:199-205.
24. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011;17:4166-73.
25. Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016;48:367-73.
26. Yang SK, Hong M, Baek J, Choi H, Zhao W, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017-20.
27. Chiengthong K, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 2016;101:e24-6.
28. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:1639-50.
29. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
30. Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One 2013;8:e58489.
31. Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 2006;12:1299-307.
32. Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, et al. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther 2013;345:95-101.
33. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther 2016;99:363-9.
34. Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol 2015;29:219-37.
35. Kovac AL. Comparative Pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting. Drugs 2016;76:1719-35.
36. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996;24:602-9.
37. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, et al. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994;38:557-66.
38. Gaedigk A, Simon S, Pearce R, Bradford LD, Kennedy MJ, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
39. Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol 2017;73:1589-98.
40. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75.
41. Thota K, Prasad K, Basaveswara RMV. Detection of cytochrome P450 polymorphisms in breastcancer patients may impact on tamoxifen therapy. Asian Pac J Cancer Prev 2018;19:343-50.
42. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52.
43. Maor R, Sara JDS, Wanous AA, Maor E, Pruthi S, et al. Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer. Coron Artery Dis 2018;29:687-93.
44. Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity. Oncologist 2016;21:795-803.
45. Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 2016;102:37-46.
46. Lui G, Bouazza N, Denoyelle F, Moine M, Brugières L, et al. Association between genetic polymorphisms and platinum-induced ototoxicity in children. Oncotarget 2018;9:30883-93.
47. Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 2013;34:458-69.
48. Liberman PHP, Goffi-Gomez MVS, Schultz C, Jacob PL, de Paula CAA, et al. Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood. Clin Transl Oncol 2018; doi: 10.1007/s12094-018-1964-7.
49. Brown AL, Lupo PJ, Okcu MF, Lau CC, Rednam S, et al. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med 2015;4:1679-86.
50. Lopes-Aguiar L, Costa EFD, Nogueira GAS, Lima TRP, Visacri MB, et al. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Oncotarget 2017;8:16190-201.
51. Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, et al. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol 2017;3:1558-62.
52. Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, et al. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 2015;16:323-32.
53. Ross CJD, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345-9.
54. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013;94:243-51.
55. Yang JJ, Lim JYS, Huang J, Bass J, Wu J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 2013;94:252-9.
56. Thiesen S, Yin P, Jorgensen AL, Zhang JE, Manzo V, et al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenet Genomics 2017;27:213-22.
57. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ. Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur J Clin Pharmacol 2007;63:703-6.
58. Hagleitner MM, Coenen MJH, Patino-Garcia A, De Bont ESJM, Gonzalez-Neira A, et al. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One 2014;9:e115869.
59. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003;22:7403-13.
60. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol 2002;39:163-7.
61. Shaikh F, Nathan PC, Hale J, Uleryk E, Frazier L. Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials. Pediatr Blood Cancer 2013;60:587-92.
62. Kolinsky DC, Hayashi SS, Karzon R, Mao J, Hayashi RJ. Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol 2010;32:119-23.
63. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, et al. Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Pediatrics 2010;125:e938-50.
64. Ellison LF, Pogany L, Mery LS. Childhood and adolescent cancer survival: a period analysis of data from the Canadian Cancer Registry. Eur J Cancer 2007;43:1967-75.
65. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology 2007;7:122-8.
66. Minotti G. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
67. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007;7:56-60.
68. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015;47:1079-84.
69. Aminkeng F, Ross CJD, Rassekh SR, Hwang S, Rieder MJ, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol 2016;82:683-95.
70. Visscher H, Ross CJD, Rassekh SR, Sandor GSS, Caron HN, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013;60:1375-81.
71. Ryerson AB, Border WL, Wasilewski-Masker K, Goodman M, Meacham L, et al. Assessing anthracycline-treated childhood cancer survivors with advanced stress echocardiography. Pediatr Blood Cancer 2015;62:502-8.
72. Tuzovic M, Wu PT, Kianmahd S, Nguyen KL. Natural history of myocardial deformation in children, adolescents, and young adults exposed to anthracyclines: systematic review and meta-analysis. Echocardiography 2018;35:922-34.
73. Rose-Felker K, Border WL, Hong BJ, Chow EJ. Cardio-oncology related to heart failure: pediatric considerations for cardiac dysfunction. Heart Failure Clinics 2017;13:311-25.
